BB Biotech Ventures

Total investments

49

Average round size

43M

Portfolio companies

29

Rounds per year

1.58

Lead investments

2

Follow on index

0.41

Exits

12

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyDrug DiscoveryPharmaceuticalsHealth CareHealth DiagnosticsMedical DeviceMedicalPharmaceuticalTherapeuticsWomen's

Investments analytics

Analytics

Total investments
49
Lead investments
2
Exits
12
Rounds per year
1.58
Follow on index
0.41
Investments by industry
  • Biotechnology (43)
  • Health Care (34)
  • Pharmaceutical (19)
  • Medical (19)
  • Health Diagnostics (15)
  • Show 17 more
Investments by region
  • United States (28)
  • Switzerland (11)
  • Netherlands (3)
  • Germany (3)
  • Ireland (2)
  • Show 1 more
Peak activity year
2011
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
18
Avg. valuation at time of investment
377M
Group Appearance index
0.98
Avg. company exit year
9
Avg. multiplicator
10.29
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company nameDeal dateIndustryDeal stageDeal sizeLocation
audiobridge13 May 2020Mobile, Music, iOS, AudioSeed68KUnited States, California, Oakland
Backpro29 Aug 2022Computer, Industrial, Industrial AutomationSeedGangwon-do, South Korea, South Korea
BioXell20 Oct 2004Biotechnology, Education, Medical, AssociationLate Stage Venture27MLombardy, Milan, Italy
Harbour Biomed09 Jul 2020Biotechnology, Pharmaceutical, BiopharmaLate Stage Venture102MShanghai, China
Rivus Pharmaceuticals22 Sep 2022Biotechnology, Health Care, Medical, PharmaceuticalEarly Stage Venture132MUnited States, Virginia, Charlottesville
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.